> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# GSK Says Arexvy Protects Over Three RSV Seasons
- URL: https://www.fdaweb.com/gsk-says-arexvy-protects-over-three-rsv-seasons/
- Published: 2024-10-09T12:00:00.000Z
- Updated: 2026-09-14T14:43:34.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5157943

GSK says the latest trial data on its Arexvy respiratory syncytial virus (RSV) vaccine indicate protection through three RSV seasons. A company [statement](https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-data-for-arexvy-its-rsv-vaccine-indicating-protection-over-three-rsv-seasons/?ref=fdaweb.com) says Arexvy is the only RSV vaccine with efficacy and safety data available through three full seasons, including in people at increased risk.

The company says Arexvy contains recombinant RSV glycoprotein F stabilized in the prefusion conformation. The antigen is combined with GSK’s proprietary ASO1E adjuvant, it says.